Document is current

Article History

Received: 27 September 2020

Accepted: 20 November 2020

First Online: 6 January 2021

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: Paolo A. Ascierto (PAA): consultant/advisory role for Bristol Myers-Squibb, Roche-Genentech, Merck Sharp & Dohme, Array, Novartis, Merck Serono, Pierre Fabre, Incyte, NewLink Genetics, Genmab, Medimmune, AstraZeneca, Syndax, SunPharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar. He also received research funds from Bristol Myers-Squibb, Roche-Genentech, Array, and travel support from MSD. Lisa H. Butterfield (LHB): scientific advisor: Calidi, SapVax, NextCure, Replimmune, Western Oncolytics, Torque/Repertoire, Pyxis, Cytomix, Roche-Genentech, Khloris, Adaptimmune, RAPT, DCPrime. Katie Campbell (KC): she received funds from Geneoscopy LLC. Bruno Daniele (BD): consulting fee or honorarium from Bayer, Eisai, Lilly, Ipsen, Astra Zeneca, MSD, Sanofi, Roche. Michael Dougan (MD): several research/financial ties to Novartis Pharmaceutics, consultant for Tillots, Partners Therapeutics, and Genentech. He is on the scientific advisory board for Neoleukin Therapeutics. Leisha A. Emens (LAE): honoraria from AbbVie, Amgen, Celgene, Chugai, Gritstone, MedImmune, Peregrine, and Syndax; honoraria and travel support from AstraZeneca, Bayer, MacroGenics, Replimune, Vaccinex; travel support from Bristol Myers-Squibb, Genentech/Roche, and Novartis; has potential future stock from Molecuvax; institutional support from Aduro Biotech, AstraZeneca, the Breast Cancer Research Foundation, Bristol Myers-Squibb, Corvus, the US Department of Defense, EMD Serono, Genentech/Roche, Maxcyte, Merck, the National Cancer Institute, the NSABP Foundation, Roche, Tempest, the Translational Breast Cancer Research Consortium, and HeritX; and reports royalties from Aduro. Silvia Formenti (SF): Grant/Research support from: Bristol Myers Squibb, Varian, Eli-Lilly, Janssen, Regeneron, Eisai, Merck. Honoraria from: Bayer, Bristol Myers Squibb, Varian, ViewRay, Elekta, Janssen, Regeneron, GlaxoSmithKline, Eisai, Astra Zeneca, MedImmune, Merck US, EMD Serono/Merck. Filip Janku (FJ): has research support through the institution from Novartis, Genentech, BioMed Valley Discoveries, Astellas, Agios, Plexxikon, Deciphera, Piqur, Symphogen, Bristol-Myers Squibb, Asana, Ideaya Biosciences, Synthorx, FujiFilm Pharmaceuticals, Sotio, Synlogic, Sanofi, SpringBank Pharma and Proximagen; is or has been on the Scientific Advisory Boards of Guardant Health, Illumina, Ideaya Biosciences, IFM Therapeutics, Synlogic, Sotio, Puretech Health, Asana and Deciphera; is a paid consultant for Cardiff Oncology and Immunomet; and has ownership interests in Cardiff Oncology. Samir N Khleif (SNK): Advisory Board/Board Member: Northwest Bio, UbiVac, Syndax Pharmaceuticals, PDS Biotechnology, KAHR, AratingaBio INC, IO Biotechnology, CanImGuide Therapeutics, Bioline Therapeutics, McKinsey Cancer Center, McKinsey and Company, Incyte, Cancer Panel, LLC Advaxis Immunetherpies; KOL/Consultant: J&J, AstraZeneca, NewLink Genetics, Medimmune, Lycera, Berringer Engelheim; Unrestricted preclinical Research funding: AstraZeneca, Bioline Therapeutics, Lycera, IO Biotech, Syndax, Biotechnologies. Tomas Kirchhoff (TK): Nothing to disclose. Alessandro Morabito (AM): He has relationships with Roche, AstraZeneca, BMS, Pfizer, MSD, Boehringer. Yana Najjar (YN): Research Funding: Merck. Consulting Fees: Array Biopharma. Speaker: Med Learning Group. Paul Nathan (PN): He received the funding from AZ, BMS, Immunocore, Ipsen, Incyte, MSD, Merck, Novartis, Pfizer, Pierre Fabre, Roche. Kunle Odunsi (KO): In the past two years funding from: AstraZeneca, Tesaro Pharma; Scientific Advisory Boards: Immunovaccine, Unleash Immuno-Oncolytics, Merck, Celsion, Truvax, Geneos, Triumvira; Co-founder: Tactiva Therapeutics. Akash Patnaik (AP): Consultancy: Janssen, Exelixis, Jounce Therapeutics. Grant/Research support: BMS. Clinical Trial Support: BMS, Clovis Oncology, Progenics, Janssen. Honoraria: Exelixis, Janssen, Roche, Clovis Oncology, Merck, Prime. Chrystal M. Paulos (CMP): Lycera, Ares Immunotherapy, Thermofisher, Obsidian Therapeutics. Bradley I. Reinfeld (BIR): Nothing to disclose. Heath D. Skinner (HDS): Nothing to disclose. John Timmerman (JT): Research support from Kite/Gilead, Merck, BMS, Spectrum Pharmaceuticals; advisory board member/consultant for Kite/Gilead, BMS, Celgene. Igor Puzanov (IP): Consultant, research funding to institutional Amgen, Nektar, ADC, Idera Pharmaceutical.